ankyrin repeat and SOCS box containing 11Genealiases: []
Q-omics provides the consensus-scored ASB11 profile across patient tissues and cancer cell-line models. ASB11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ASB11 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ASB11 RNA expression shows 12,672 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where ASB11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASB11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASB11 survival associations across molecular data types. ASB11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASB11 RNA expression–survival associations across cancer types. High ASB11 expression shows unfavorable associations in UVM, COAD, THYM, MESO and KIRP, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ASB11 RNA expression.
This table summarizes ASB11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ASB11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASB11 shows lower tumor expression in HNSC, LUSC, STAD, KIRC and COAD and higher tumor expression in KICH. The HNSC box plot shows higher ASB11 RNA expression in normal versus tumor tissue (log2 FC = −1.498, t-test p < 0.001).
This table shows molecular features associated with ASB11 in patient tissues and cancer cell lines. In patient samples, ASB11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ASB11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
